# Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

> **NCT06107673** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 144 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib
- **DRUG:** Aromatase inhibitor
- **DRUG:** Docetaxel injection
- **DRUG:** Epirubicin Hydrochloride Injection
- **DRUG:** Cyclophosphamide injection

## Key facts

- **NCT ID:** NCT06107673
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-30
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06107673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06107673, "Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06107673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*